Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats

The pulmonary route is an alternative route of administration for the systemic delivery of peptide and proteins with short‐half lives. A long‐acting formulation of insulin was prepared by encapsulation of protein into respirable, biodegradable microcapsules prepared by an oil in oil emulsification/solvent evaporation method. Insulin‐loaded PLGA microcapsules prepared as a dry powder inhaler formulation were administered via the pulmonary route to diabetic rats and serum insulin and glucose concentrations were monitored. Control treatments consisted of respirable spray‐dried insulin (RSDI) powder administered by intratracheal insufflation, insulin‐loaded PLGA microcapsules and NPH (long‐acting) insulin administered by subcutaneous (SC) administration. Pharmacokinetic analysis demonstrated that insulin administered in PLGA microcapsules illustrated a sustained release profile which resulted in a longer mean residence time, 4 and 5 fold longer than those after pulmonary administration of RSDI and SC injection of NPH insulin, respectively. Accordingly, the hypoglycemic profile followed a stable and sustained pattern which remained constant between 10 and 48 h. Results of the in vitro experiments were in good agreement with those of in vivo studies. Bronchoalveolar lavage fluid analysis indicated that microcapsules administration did not increase the activities of lactate dehydrogenase and total protein. However, histological examination of the lung tissue indicated a minor but detectable effect on the normal physiology of the rat lung. These findings suggest that the encapsulation of peptides and proteins into PLGA microcapsules technique could be a promising controlled delivery system for pulmonary administration. Copyright © 2010 John Wiley & Sons, Ltd.

[1]  J. Emami,et al.  A novel approach to prepare insulin-loaded poly(lactic-co-glycolic acid) microcapsules and the protein stability study. , 2009, Journal of pharmaceutical sciences.

[2]  H. Mirzadeh,et al.  Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology , 2009, Journal of microencapsulation.

[3]  Y. Kawashima,et al.  Histological examination of PLGA nanospheres for intratracheal drug administration. , 2008, International journal of pharmaceutics.

[4]  W. Hennink,et al.  Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Chan‐Wha Kim,et al.  Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. , 2007, International journal of pharmaceutics.

[6]  F. Ahsan,et al.  Inhaled Insulin is Better Absorbed When Administered as a Dry Powder Compared to Solution in the Presence or Absence of Alkylglycosides , 2006, Pharmaceutical Research.

[7]  M. Rawlins,et al.  Inhaled insulin , 2006, The Lancet.

[8]  J. Gobburu,et al.  Population Pharmacokinetic–Pharmacodynamic Modeling of Subcutaneous and Pulmonary Insulin in Rats , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  M. Sakagami,et al.  The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  L. Heinemann,et al.  Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. , 2005, Diabetes care.

[11]  王姮,et al.  Inhaled insulin , 2005 .

[12]  Chan‐Wha Kim,et al.  Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  B. Zinman,et al.  Alternative routes of insulin delivery , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[14]  F. Ahsan,et al.  Pulmonary Absorption of Insulin Mediated by Tetradecyl-β-Maltoside and Dimethyl-β-Cyclodextrin , 2003, Pharmaceutical Research.

[15]  K Surendrakumar,et al.  Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[16]  D. Lison,et al.  Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. , 2003, Journal of pharmaceutical sciences.

[17]  A. Hickey,et al.  Facilitation of Pulmonary Insulin Absorption by H-MAP: Pharmacokinetics and Pharmacodynamics in Rats , 2001, Pharmaceutical Research.

[18]  A. Hickey,et al.  Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. , 2001, Critical reviews in therapeutic drug carrier systems.

[19]  A. Klibanov,et al.  Inhalation delivery of proteins from ethanol suspensions , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Okamoto,et al.  Effect of additives on insulin absorption from intratracheally administered dry powders in rats. , 2001, International journal of pharmaceutics.

[21]  H. Okamoto,et al.  A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. , 2000, Journal of pharmaceutical sciences.

[22]  R. Langer,et al.  Biomaterials in drug delivery and tissue engineering: one laboratory's experience. , 2000, Accounts of chemical research.

[23]  T. Nagai,et al.  Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations. , 1999, International journal of pharmaceutics.

[24]  H. Takeuchi,et al.  Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[25]  R. Langer,et al.  Large Porous Particles for Sustained Protection from Carbachol-Induced Bronchoconstriction in Guinea Pigs , 1999, Pharmaceutical Research.

[26]  Paalzow,et al.  Pharmacodynamic aspects of drug administration. Tolerance development. , 1998, Advanced drug delivery reviews.

[27]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[28]  Johnson,et al.  Preparation of peptide and protein powders for inhalation. , 1997, Advanced drug delivery reviews.

[29]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[30]  S. Newman,et al.  Effect of different modes of inhalation on drug delivery from a dry powder inhaler , 1994 .

[31]  F. Komada,et al.  Intratracheal delivery of insulin Absorption from solution and aerosol by rat lung , 1992 .

[32]  M. F. Khan,et al.  Cellular and biochemical indices of bronchoalveolar lavage for detection of lung injury following insult by airborne toxicants. , 1991, Toxicology letters.

[33]  R. Henderson Use of bronchoalveolar lavage to detect lung damage. , 1984, Environmental health perspectives.

[34]  E. G. Damon,et al.  Early damage indicators in the the lung I. Lactate dehydrogenase activity in the airways. , 1978, Toxicology and applied pharmacology.

[35]  S J Enna,et al.  Absorption of saccharides and urea from the rat lung. , 1972, The American journal of physiology.

[36]  G. Dailey Developing a pulmonary insulin delivery system for patients with diabetes. , 2007, Clinical therapeutics.

[37]  T. Vandamme,et al.  Pulmonary drug delivery systems: recent developments and prospects. , 2002, Critical reviews in therapeutic drug carrier systems.

[38]  F. Lieutier-Colas [Deposition of particles in the respiratory tract]. , 2001, Allergie et immunologie.

[39]  Y. Chien,et al.  Novel methods of insulin delivery: an update. , 1998, Critical reviews in therapeutic drug carrier systems.

[40]  C. M. Agrawal,et al.  Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. , 1996, Biomaterials.